ImmuPharma (LON:IMM) Issues Quarterly Earnings Results

ImmuPharma (LON:IMM – Get Free Report) announced its earnings results on Wednesday. The company reported GBX (0.37) earnings per share (EPS) for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 6,634.51% and a net margin of 3,519.56%.

ImmuPharma Price Performance

IMM opened at GBX 4.70 on Wednesday. The company’s 50 day simple moving average is GBX 4.63 and its two-hundred day simple moving average is GBX 6.31. ImmuPharma has a 1-year low of GBX 1.39 and a 1-year high of GBX 19.40. The firm has a market capitalization of £29.29 million, a price-to-earnings ratio of -5.28 and a beta of 2.98.

Get ImmuPharma alerts:

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

• Five stocks we like better than ImmuPharma
• AI Can’t Reach the Real World Without These 3 Stocks
• Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
• 2 Aluminum Stocks Poised for Big Tariff-Related Gains
• AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.